Cantor Fitzgerald Reaffirms “Overweight” Rating for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a research report issued to clients and investors on Wednesday,Benzinga reports.

A number of other equities research analysts have also recently weighed in on the stock. Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Leerink Partners cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $60.00 to $56.00 in a research note on Friday, September 27th. Royal Bank of Canada raised their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Finally, Raymond James reiterated an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $56.33.

Agios Pharmaceuticals Trading Down 8.2 %

AGIO stock opened at $35.81 on Wednesday. The stock has a market cap of $2.04 billion, a P/E ratio of 3.15 and a beta of 0.80. Agios Pharmaceuticals has a twelve month low of $20.96 and a twelve month high of $62.58. The company’s 50 day moving average is $49.94 and its two-hundred day moving average is $46.71.

Insider Transactions at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. This trade represents a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.93% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Large investors have recently modified their holdings of the business. Northcape Wealth Management LLC acquired a new stake in Agios Pharmaceuticals in the second quarter valued at $244,000. Bank of New York Mellon Corp grew its holdings in shares of Agios Pharmaceuticals by 13.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 223,151 shares of the biopharmaceutical company’s stock worth $9,622,000 after acquiring an additional 27,193 shares during the period. Panagora Asset Management Inc. purchased a new position in Agios Pharmaceuticals in the 2nd quarter valued at approximately $7,540,000. TD Asset Management Inc raised its holdings in Agios Pharmaceuticals by 34.6% during the second quarter. TD Asset Management Inc now owns 210,472 shares of the biopharmaceutical company’s stock worth $9,076,000 after purchasing an additional 54,054 shares during the last quarter. Finally, North Star Asset Management Inc. purchased a new stake in Agios Pharmaceuticals during the second quarter worth $216,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.